Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dyne Therapeutics's ROE % for the quarter that ended in Jun. 2026 was -91.15%. Dyne Therapeutics's PB Ratio for the quarter that ended in Jun. 2026 was 5.24.
Dyne Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2026 was -17.40%.
Dyne Therapeutics ROE % Adjusted to Book Value Related Terms
Dyne Therapeutics ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Dyne Therapeutics's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dyne Therapeutics ROE % Adjusted to Book Value Chart
DYN vs VKTX, CELC, RLAY: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Dyne Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dyne Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dyne Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Dyne Therapeutics's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -17.40% mean?
Dyne Therapeutics (DYN) has a ROE % Adjusted to Book Value of -17.40% as of Jun. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Dyne Therapeutics and its competitors.
Is Dyne Therapeutics' ROE % Adjusted to Book Value too high?
Dyne Therapeutics' current ROE % Adjusted to Book Value is -17.40%. Overall, Dyne Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Dyne Therapeutics' ROE % Adjusted to Book Value compare to VKTX and CELC?
Dyne Therapeutics' ROE % Adjusted to Book Value of -17.40% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Dyne Therapeutics and its competitors. Dyne Therapeutics's current ROE % Adjusted to Book Value is -17.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dyne Therapeutics stock overvalued right now?
Dyne Therapeutics (DYN) has a current ROE % Adjusted to Book Value of -17.40%. The current ROE % Adjusted to Book Value is -17.40%. Dyne Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Dyne Therapeutics (DYN), the current ROE % Adjusted to Book Value is -17.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
34GF Score
Get the complete analysis for DYN
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DYN has been successfully added to your 
